Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM
Key Highlights
- ➤Acoramidis cut first heart-failure event risk 45% versus placebo by Month 30
- ➤Acoramidis lowered ODI risk 23% versus tafamidis in German real-world data
- ➤Continuous acoramidis reduced heart-failure mortality risk 58% through Month 54
- ➤TTR stabilizers captured 81.4% of newly treated U.S. ATTR-CM patients
- ➤Acoramidis’ early eGFR dip showed stable kidney function through 30 months in CKD stage 4
Expert Statements
Mazen Hanna, M.D. of Cleveland Clinic
“ATTR-CM causes heart failure in our patients when misfolded transthyretin proteins build up as amyloid fibrils in the heart muscle, making the walls stiff and rigid. It is the cause of urgent doctor visits, hospital stays, and, ultimately, death, so preventing these events matters most to people with ATTR-CM, their families and their care teams”
Mazen Hanna, M.D. of Cleveland Clinic
“In this analysis, acoramidis reduced the risk of a first heart failure event by 45%, with separation from placebo within the first month and lower rates of every type of heart failure event we looked at, from outpatient diuretic intensification through hospitalization and heart failure death. Seeing an effect that early, and across a broad range of patients, is meaningful for a disease where time matters. This is strong validation that early treatment with acoramidis can improve clinical outcomes.”
* In real-world German data from the Bayer-led mODIficATTR study, acoramidis was associated with a 23% lower risk of ODI, an early marker of worsening HF, versus tafamidis (adjusted HR 0.77; 95% CI 0.61–0.98; p=0.04), building on consistent results from the Wright et al. Komodo claims analysis (34% reduction in clinical worsening events; p=0.046) and the independently conducted Lanfear et al. Epic COSMOS electronic health record (EHR) study (27% lower risk of cardiovascular hospitalization; p<0.001) * This is also consistent with the ATTRibute-CM trial, in which acoramidis reduced the risk of a first HF-specific event by 45% versus placebo (HR 0.55; 95% CI 0.44–0.69; p<0.001) with benefit emerging within the first month of treatment * Benefit extended to every type of HF event with fewer HF deaths, HF hospitalizations, and outpatient worsening HF events for acoramidis versus placebo, and directionally consistent results across all prespecified subgroups * Continuous acoramidis was associated with a durable reduction in HF mortality through 54 months (HR 0.42; 95% CI 0.27–0.65; p<0.001) * Series of six kidney analyses of ATTRibute-CM indicated that acoramidis’ early eGFR dip associated with potentially rapid kidney-protective activity was: (i) consistently observed irrespective of baseline AF status, diabetes status, RAAS inhibitor use, and genotype with favorable clinical outcomes observed through Month 30 across all of these subgroups, (ii) not accompanied by any negative, clinically meaningful changes in laboratory measures or blood pressure, and (iii) did not lead to clinically meaningful changes in markers of kidney safety in participants with CKD stage 4, whose kidney function remained stable over 30 months * Real-world treatment patterns indicate that TTR stabilizers remain the predominant first-line therapy of choice for ATTR-CM with 81.4% of newly treated patients initiating TTR stabilizer monotherapy * Together, these data reinforce the speed and breadth of acoramidis' benefit on the outcomes that matter most to people living with ATTR-CM PALO ALTO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced that new Phase 3 ATTRibute-CM analyses and real-world evidence for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, and the XX International Symposium on Amyloidosis (ISA) 2026 in Montevideo, Uruguay. At AHA 2026, BridgeBio had 2 moderated posters and 3 posters, and at ISA 2026, BridgeBio had 28 total abstracts accepted comprising 12 new poster presentations and 16 encore poster presentations. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
Get started
Create a free account to read the full story.
